Rochester, Minnesota


Delivery of therapeutic proteins into the nervous system

  • Quantitative assessment of the permeability of peptides and proteins at the blood-brain barrier and blood-nerve barrier.
  • Protein modifications to increase permeability at the blood-brain barrier and blood-nerve barrier: glycation, polyamine modification (putrescine, spermine, spermidine), ubiquitin modification.
  • Delivery of therapeutic proteins across the blood-brain/nerve barriers after systemic administration for the treatment of neurodegenerative diseases.
  • Proteins targeted for delivery: neurotrophic factors, anti-oxidant enzymes (superoxide dismutase, catalase), leptin, peptides that inhibit amyloidogenesis, interferons, cytokines, antibodies, interleukins, etc.
  • In vivo targeting of Alzheimer's amyloid plaques for diagnostic imaging.
  • Pre-clinical animal models to demonstrate efficacy of our delivery technology include:
Animal Models Therapy
Transgenic mouse model of FALS with a point mutation of Gly 93 Ala in SOD Antioxidant enzymes
Transgenic mouse models of Alzheimer's disease that overexpress human A βprotein Peptides that inhibit amyloidogenesis, antioxidant enzymes, antibodies to A β
Obesity Leptin
Diabetic neuropathy: Modulation of DRG trkA and p75 NGF receptors after peripheral axotomy NGF
Four-vessel occlusion model of cerebral ischemia (stroke) Anti-oxidant enzymes


See my publications


Primary Appointment

  1. Neurology

Joint Appointment

  1. Biochemistry

Academic Rank

  1. Professor of Neurology


  1. Post Doctoral Fellowship - National Multiple Sclerosis Society National Institutes of Health
  2. PhD - Biochemistry (Neurological Sciences) University of Pennsylvania
  3. Predoctoral Fellowship - (USPHSG), Institute of Neurological Sciences University of Pennsylvania
  4. BA - Chemistry College of Wooster
  5. Research Training Department of Neurology, Albert Einstein College of Medicine

View my Pure Experts profile

Mayo Clinic Footer